Cytosorbents Crp (CTSO) Fair Value & Analysis
Healthcare · US · Market cap $27.5M · ISIN US23283X2062
Cytosorbents Crp
CTSO · US
Strengths
Risks
Fair value as of: Aug 27, 2026
From 3 valuation models · updated 2 days ago
Share price −5.1% over the past month.
Below-average quality, trading 66% below our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (36/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case ($0.5355). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($0.5355 to $1.36) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range $0.3111 – $9.71 · fair‑value band $0.5355 – $1.36 · the $0.3360 price screens below the $0.9775 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Cytosorbents Crp (CTSO) currently trades at $0.3360, while our model-based Fair Value estimate is $0.9775, implying the stock looks roughly 190.9% undervalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Cytosorbents Crp generated revenue of $37.2M at a net margin of -31.9%. Revenue grew 1.6% year over year. Net debt stands at $22.9M. Fundamentals as of Aug 27, 2026
Our scenario range runs from $0.5355 (bear case) to $1.36 (bull case); at $0.3360, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 76% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at 191%, CTSO screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Dividend Discount ($0.8800) versus Asset-Based ($0.0600). Highest evidence: Gordon GGM (70).
Notify me when CTSO reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 36 · Market factors (momentum, volatility) 6
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally.
Full company description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cytosorbents Crp reported revenue of $37.1M in FY2025 versus $40.1M in FY2021, a compound −2.0%/yr. Reported net income was −$8.2M in FY2025.
Watch CTSO: get an alert when its fair value changes →
Peer Group
Medical Devices · 363 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $114.10 | $74.79 | -34% |
| Stryker Corporation SYK | $322.12 | $186.28 | -42% |
| Medtronic plc MDT | $89.97 | $65.57 | -27% |
| Boston Scientific Corporation BSX | $48.17 | $30.73 | -36% |
| Edwards Lifesciences Corporation EW | $90.78 | $41.02 | -55% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | -14% |
| DexCom, Inc DXCM | $88.96 | $38.95 | -56% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | -14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | -39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | -2% |
Compare Cytosorbents Crp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Cytosorbents Crp (CTSO) overvalued or undervalued?
What is the fair value of CTSO?
What is the quality score of CTSO?
What is the revenue of Cytosorbents Crp (CTSO)?
What is the net profit margin of CTSO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Cytosorbents Crp in the live analysis
One click puts Cytosorbents Crp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.